Literature DB >> 33627057

hsa-miR-9-5p Down-Regulates HK2 and Confers Radiosensitivity to Nasopharyngeal Carcinoma.

Shanqiang Zhan1, Baoliang Ni1.   

Abstract

BACKGROUND: This study was designed to explore the effects of hsa-miR-9-5p on radiotherapy sensitivity of nasopharyngeal carcinoma (NPC) by targeting hexokinase 2 (HK2).
METHODS: The levels of hsa-miR-9-5 and HK2 in NPC patients and radiosensitive and resistant cells were determined using qRT-PCR. The dual luciferase reporter gene system was used to determine hsa-miR-9-5p targeting HK2. The level of HK2 expression in NPC were determined using qRT-PCR and western blotting after the administration of hsa-miR-9-5p agomir. The effects of hsa-miR-9-5p on proliferation and apoptosis with or without irradiation (IR) were examined using CCK-8, flow cytometry and colony formation assays. (18F)-Flourodeoxyglucose uptake was used to evaluate the growth of tumor with or without radiation therapy in vivo.
RESULTS: hsa-miR-9-5p target to inhibit HK2. Moreover, the cell proliferation was seen in a decreased trend while the cell apoptosis increased in the hsa-miR-9-5p group following radiation therapy hsa-miR-9-5p also showed a significant inhibitory effect on the growth of tumor in vivo with radiation therapy.
CONCLUSIONS: hsa-miR-9-5p improved the radiosensitivity of NPC by targeting HK2.

Entities:  

Keywords:  hexokinase 2; hsa-miR-9-5p; nasopharyngeal carcinoma; radiation

Year:  2021        PMID: 33627057     DOI: 10.1177/1533033821997822

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  2 in total

1.  LINC01116 Promotes Migration and Invasion of Oral Squamous Cell Carcinoma by Acting as a Competed Endogenous RNA in Regulation of MMP1 Expression.

Authors:  Yukang Ying; Dong Liu; Yue Zhao; Yuan Zhong; Xuhui Xu; Jun Luo; Zhenxing Zhang
Journal:  Comput Math Methods Med       Date:  2022-06-17       Impact factor: 2.809

2.  Targeted Inhibition of HK-II Reversed the Warburg Effect to Improve the Radiosensitivity of Laryngeal Carcinoma.

Authors:  Xiao-Hong Chen; Ding-Li Yu; Jiang-Tao Zhong; Shui-Hong Zhou; Jun Fan; Zhong-Jie Lu
Journal:  Cancer Manag Res       Date:  2021-10-27       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.